RESEARCHER PROFILE

Chloe Shay

← Back to The Wallace H. Coulter Department of Biomedical Engineering

C

The Wallace H. Coulter Department of Biomedical Engineering

Head and Neck Cancer StudiesCancer, Hypoxia, and MetabolismCancer Cells and MetastasisFibroblast Growth Factor ResearchNanoparticle-Based Drug Delivery

Chloe Shay works in Head and Neck Cancer Studies, Cancer, Hypoxia, and Metabolism, Cancer Cells and Metastasis, Fibroblast Growth Factor Research, Nanoparticle-Based Drug Delivery. Recorded institutional associations include Georgia Institute of Technology, Emory University, The Wallace H. Coulter Department of Biomedical Engineering.

122Publications
1,389Citations
23H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Cancer metabolism and carcinogenesis

    2024 · 138 citations
  2. Targeting ROS-Mediated Crosstalk Between Autophagy and Apoptosis in Cancer

    2020 · 129 citations
  3. PFKP Signaling at a Glance: An Emerging Mediator of Cancer Cell Metabolism

    2019 · 93 citations
  4. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4–GSK3β–Nrf2 Signaling

    2017 · 85 citations
  5. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma

    2018 · 80 citations
  6. Cell death shapes cancer immunity: spotlighting PANoptosis

    2024 · 79 citations
  7. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

    2023 · 69 citations
  8. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression

    2018 · 59 citations
  9. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

    2019 · 57 citations
  10. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib

    2018 · 55 citations
  11. Nck-associated protein 1 associates with HSP90 to drive metastasis in human non-small-cell lung cancer

    2019 · 49 citations
  12. Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer

    2021 · 48 citations
  13. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis

    2019 · 46 citations
  14. Circumventing AKT-Associated Radioresistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capivasertib

    2020 · 42 citations
  15. ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development

    2022 · 39 citations
  16. SHOX2 cooperates with STAT3 to promote breast cancer metastasis through the transcriptional activation of WASF3

    2021 · 34 citations
  17. PGK1: An Essential Player in Modulating Tumor Metabolism

    2021 · 34 citations
  18. Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CYT997 through enhancing excessively high reactive oxygen species-induced apoptosis

    2018 · 32 citations
  19. Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics

    2017 · 30 citations
  20. Tumor secretome shapes the immune landscape during cancer progression

    2025 · 27 citations
  21. ATAD3A on the Path to Cancer

    2019 · 26 citations
  22. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis

    2021 · 26 citations
  23. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report

    2017 · 25 citations
  24. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity

    2017 · 23 citations
  25. Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer

    2023 · 18 citations
  26. The New Frontier of Three-Dimensional Culture Models to Scale-Up Cancer Research

    2021 · 14 citations
  27. PI3K Isoform-Selective Inhibitors in Cancer

    2020 · 12 citations
  28. Unveiling Tumor Microenvironment Interactions Using Zebrafish Models

    2021 · 7 citations
  29. Exploring the impact of GSTM1 as a novel molecular determinant of survival in head and neck cancer patients of African descent

    2024 · 5 citations
  30. Multifaceted Roles of Long Non-coding RNAs in Head and Neck Cancer

    2021 · 3 citations
  31. Visualizing and Evaluating Cancer Cell Growth and Invasion by a Novel 3D Culture System

    2020 · 1 citations
  32. Evaluating the Anticancer Activity of Natural Products Using a Novel 3D Culture Model

    2021 · 1 citations
  33. Supplementary Figure S4 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer

    2023 · 1 citations
  34. Glycolytic cancer-associated fibroblasts orchestrate metabolic remodeling in the tumor microenvironment

    2026 · 1 citations
  35. Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity

    2026 · 1 citations
  36. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity

    2017 · 0 citations
  37. Abstract 853: Essential role of autocrine FGF19-FGFR4 signaling in head and neck tumorigenesis

    2019 · 0 citations
  38. Abstract 2114: Co-delivery nanoparticle to overcome therapeutic resistance in human head and neck cancer promoted by insufficient Src-targeted treatment

    2019 · 0 citations
  39. Abstract B09: Inactivating the EGFR-Arf1 axis by HDAC-targeted therapy to suppress invasiveness of head and neck squamous cell carcinoma

    2020 · 0 citations
  40. Devimistat induces reprogramming of glycolytic metabolism to augment its anticancer potency in head and neck cancer

    2020 · 0 citations
  41. Abstract PO-130: The mitochondrial protein ATAD3A promotes cisplatin resistance in oral squamous cell carcinoma

    2020 · 0 citations
  42. ヒストン脱アセチル化酵素阻害剤はEGFR-Arf1軸のヒストンアセチル化非依存性遮断を介して頭頸部扁平上皮癌の攻撃性を抑制する【JST・京大機械翻訳】

    2019 · 0 citations
  43. Abstract 853: Essential role of autocrine FGF19-FGFR4 signaling in head and neck tumorigenesis

    2019 · 0 citations
  44. Abstract 2114: Co-delivery nanoparticle to overcome therapeutic resistance in human head and neck cancer promoted by insufficient Src-targeted treatment

    2019 · 0 citations
  45. Abstract 88: ATAD3A enhances head and neck cancer malignancy via mitochondrial ERK1/2 signaling

    2022 · 0 citations
  46. Abstract 3026: Inhibition of glutaminolysis overcomes metabolic adaptation to devimistat treatment

    2022 · 0 citations
  47. Data from FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4–GSK3β–Nrf2 Signaling

    2023 · 0 citations
  48. Supplementary Figure S5 from FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4–GSK3β–Nrf2 Signaling

    2023 · 0 citations
  49. Supplementary Figure S1. from FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4–GSK3β–Nrf2 Signaling

    2023 · 0 citations
  50. Supplementary Figure S2. from FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4–GSK3β–Nrf2 Signaling

    2023 · 0 citations

← Return to the university profile